AEMD is up 84 cents US todayTo the best of my knowledge, you still only need one hand to count the human usage.
Interesting though, important types involved and our CMO was a special advisor there. As David previously mused, is this a special M&A opp? They do have a fistful of US cash, a NAS listing and the right people to get us to the right place... just my own special muse ... hmmm? Maybe David hit a single with that suggest? Perhaps of little relevance given the lack of human data, but we could crutch off the 2 FDA breakththrough designations to help the puzzle pieces fit together better. Let me know if it is going to happen, I could help write the NR and make it look more palatable. Jmho
Best,
Gadge